In re Cornerstone Therapeutics: Dismissal under 102(b)(7) Unavailable to Independent Directors when Entire Fairness Applies | Practical Law

In re Cornerstone Therapeutics: Dismissal under 102(b)(7) Unavailable to Independent Directors when Entire Fairness Applies | Practical Law

The Delaware Court of Chancery ruled in In re Cornerstone Therapeutics Stockholder Litigation that in a controlling-stockholder transaction in which the plaintiff pleads allegations of unfairness, any directors who facilitated the transaction, even if disinterested and independent, cannot obtain dismissal of the claims against them before the conclusion of the trial, even if they are indemnified under Section 102(b)(7).

In re Cornerstone Therapeutics: Dismissal under 102(b)(7) Unavailable to Independent Directors when Entire Fairness Applies

by Practical Law Corporate & Securities
Published on 12 Sep 2014Delaware
The Delaware Court of Chancery ruled in In re Cornerstone Therapeutics Stockholder Litigation that in a controlling-stockholder transaction in which the plaintiff pleads allegations of unfairness, any directors who facilitated the transaction, even if disinterested and independent, cannot obtain dismissal of the claims against them before the conclusion of the trial, even if they are indemnified under Section 102(b)(7).
In a decision that highlights a potential conflict between two lines of Delaware Court of Chancery cases, the Court ruled in In re Cornerstone Therapeutics Stockholder Litigation that an exculpation provision in a certificate of incorporation under DGCL Section 102(b)(7) does not entitle disinterested and independent directors to dismissal of claims brought against them if they have helped facilitate a transaction with a controlling stockholder that will be reviewed for entire fairness ( (Del. Ch. Sept. 9, 2014)). The decision confirms that Delaware law recognizes two sets of standards for pleadings against disinterested and independent directors:
  • In an ordinary transaction, the plaintiffs must plead with particularity how the directors breached a duty of loyalty for the claim against those directors to survive a motion to dismiss.
  • If the directors have negotiated a controller transaction that will proceed to trial under entire fairness review, the plaintiffs only need to plead the self-interest of and manipulation by the controlling stockholder and the unfairness of the transaction, without making particularized allegations that the directors breached a fiduciary duty. The directors' involvement is enough for the claim against them to survive a motion to dismiss.

Background

The facts of the case are simple and not critical to the decision on this particular motion, which only addressed the pleading standard for a motion to dismiss claims against disinterested and independent directors. Cornerstone Therapeutics, a publicly traded Delaware corporation, was majority owned by Chiesi Farmaceutici S.p.A., a privately held Italian drug manufacturer. In February 2013, Chiesi delivered an offer to the board of Cornerstone to acquire the remainder of the stock that it did not already own at a price between $6.40 and $6.70 per share. The letter did not condition the offer on the approval of a majority of a minority of the stockholders and all parties to the litigation agreed that the offer did not satisfy the test in M & F Worldwide for lowering the standard of review for a controlling-stockholder transaction.
The board of Cornerstone formed a special committee of five directors to evaluate and negotiate the offer. During the negotiations, Chiesi indicated its displeasure with the committee's position and threatened the committee members' removal from the board. Despite the threat, the committee continued to reject offers it considered low, eventually coming to agreement with Chiesi on a price of $9.50 per share. The merger agreement was eventually approved by more than 80% of the minority stockholders.
The defendants conceded that the transaction was subject to entire fairness review as a result of the controlling stockholder standing on both sides of the transaction. The motion to dismiss involved only the disinterested and independent directors who served on the special committee and approved the transaction. At issue was the pleading standard for those directors:
  • Whether the plaintiff must specifically plead that the directors themselves committed a breach of the duty of loyalty or merely that they negotiated the allegedly unfair transaction.
  • Related to that question, whether an exculpation provision adopted pursuant to Section 102(b)(7) must be ignored at the motion-to-dismiss stage to await consideration after the transaction has been reviewed for entire fairness at trial.
The plaintiffs contended that when the applicable standard of review for the transaction is entire fairness, the court must hold off on dismissing the claims against the disinterested and independent directors, in spite of the certificate of incorporation's exculpation provision. In support of that contention, the plaintiffs cited to In re Orchard Enterprises, Inc. Stockholder Litigation, which apparently stands for exactly that rule (88 A.3d 1, 37 (Del. Ch. 2014)). In response, the defendants claimed that an entire-fairness claim against the controlling stockholder does not relieve the plaintiffs of their obligation to plead a specific claim against each of the disinterested and independent directors. In support of that theory, the defendants cited to In re Southern Peru Copper Corp., in which the Court of Chancery did in fact dismiss claims against independent directors pre-trial (52 A.3d 761 (Del. Ch. 2011)). In that decision, the Court stated that "[u]nless there are facts suggesting that the directors consciously approved an unfair transaction... the more stringent, strict liability standard applicable to interested parties is critically different" than the standard applicable to the directors on the special committee (52 A.3d at 787, n.72).

Outcome

In ruling on the motion to dismiss, the Court sounded sympathetic to each side's reading of the relevant precedent and acknowledged that there is a "lack of congruity" in the case law (, at *6). To get past the apparent conflict between Orchard and Southern Peru, the Court noted that each of those cases involved motions for summary judgment on a developed factual record and were not controlling in the context of a motion to dismiss.

Doctrinal Arguments

The Court then spent most of the remainder of its memorandum opinion explaining the doctrinal underpinnings of entire fairness review for controlling-stockholder transactions and how those policies ought to influence the standard for dismissal of claims against disinterested and independent directors. Key to the Court's decision was the distinction between two sets of fiduciaries:
  • Controlling stockholders and directors who "use the corporate machinery to facilitate a self-interested transaction" and consequently are strictly liable without further proof of fault, unless they can demonstrate the entire fairness of the transaction.
  • Disinterested and independent directors, who can only be liable if they have committed a breach of a fiduciary duty that is not exculpated by a 102(b)(7) provision.
In the Court's view, the fundamental difference in the type of potential liability between these two groups has led to some lack of clarity in the case law. To plead a case sufficient to withstand a motion to dismiss with regard to a stockholder who has transacted with the corporation, the plaintiff must merely plead facts raising an inference that the defendant stockholder is a controller and that the transaction was not entirely fair to the minority. Once those pleadings are made, the matter must proceed to a trial at which the fairness of the transaction will be scrutinized.
However, the pleading standard for disinterested and independent directors charged with a breach of fiduciary duty in connection with that same transaction implicates separate policy questions. The defendants argued that the low pleading standard for an interested fiduciary cannot be the same standard for disinterested directors and that the plaintiff should have to plead particular facts alleging a breach of a non-exculpated duty. The Court agreed that "there is much... to recommend such a pleading requirement" because it is consistent with the treatment afforded directors in non-controller transactions. In those situations, the policy of Delaware law is to require specific pleadings of non-exculpated breaches in order to allow management of Delaware corporations to take risks and avoid frivolous litigation.
The Court added that "doctrinally it seems insufficient" to capture disinterested and independent directors with pleadings that they simply participated in a transaction with a controller and to allow a general inference of disloyalty to overcome a motion to dismiss. The Court noted that such a pleading requirement would create a disincentive for directors to serve on special committees because it would taint them with the overall unfairness of the controlling stockholder's involvement, which they could have avoided by refusing to participate in the negotiation of the transaction. This would also seem counter to the policy underpinnings of the Delaware Supreme Court's opinion in M & F Worldwide, which suggests that a motion to dismiss is available when the transaction is negotiated by a special committee of disinterested, independent directors who are empowered to reject the transaction and is conditioned on majority-of-the-minority approval.
The Court also gave credit to the plaintiffs' theory, acknowledging that directors' loyalties are often "cryptic and unknowable" at the pleading stage in controller transactions where there is no developed record. As the Court explained, holding directors who negotiated the transaction as defendants until a determination of entire fairness has been made, for purposes of determining at that point whether those directors breached a non-exculpated fiduciary duty, will sometimes catch wrongdoing by directors who would have already had the case against them dismissed under the defendants' higher pleading standard. However, that advantage involves a trade-off of the benefits identified by the Court.

Supreme Court Precedent

In spite of its misgivings about holding the plaintiffs to a low pleading standard regarding the independent directors, and in spite of its apparent sympathy for the defendants' arguments, the Court rejected the defendants' motion to dismiss. Regardless of the split between Orchard and Southern Peru and certain other Chancery cases, the Court here ruled that the Supreme Court's ruling in Emerald Partners II is controlling precedent (Emerald Partners v. Berlin, 787 A.2d 85 (Del. 2001)). In Emerald Partners II, the Supreme Court stated that "when entire fairness is the applicable standard of judicial review, a determination that the director defendants are exculpated from paying monetary damages can be made only after the basis for their liability has been decided" (787 A.2d at 94). As the Cornerstone Therapeutics court explained, the basis for liability is decided only when there is a fully developed factual record as to whether the transaction was entirely fair, which is after a trial. (Though it did not say so explicitly, its repeated references to a post-trial determination implies that at the stage of a motion for summary judgment, the Cornerstone Therapeutics court would agree with Orchard, contra Southern Peru, that such a motion must still be dismissed.) Consequently, the plaintiffs make a sufficient pleading when they allege that:
  • A stockholder controlled the corporate machinery.
  • That controller used that machinery to facilitate a transaction for which it stood on both sides.
  • The transaction was not entirely fair to the minority stockholders.
  • The disinterested and independent director defendants negotiated or facilitated that transaction.
That pleading is sufficient to withstand a motion to dismiss brought by the disinterested and independent directors, even when the certificate of incorporation has an exculpation provision under Section 102(b)(7) and even when the pleading makes no allegation that the directors breached a non-exculpated duty.

Support from Swomley v. Schlecht

Coincidentally, the Court of Chancery recently touched on this same issue in a separate hearing on a motion to dismiss in a transaction involving a controlling stockholder. In Swomley v. Schlecht, the Court ultimately granted a motion to dismiss from the bench, but expressed its views on this issue before it determined that the transaction satisfied the M & F Worldwide six-part test (see No. 9355-VCL, (Del. Ch. Aug. 27, 2014) (TRANSCRIPT)). Speaking from the bench, Vice Chancellor Laster stated that, "When I read Emerald, not just Emerald I but also Emerald II, the Supreme Court seemed to be saying that if you had those two things [a controller context and allegations of unfairness], you had to push off that determination until later in the case."
Vice Chancellor Laster justified that outcome by noting that under Kahn v. Lynch and its progeny, just having a special committee of disinterested and independent directors, without a non-waivable condition of minority approval, is not enough to lower the standard of review to business judgment. It is only enough to shift the burden of proof to the plaintiff, but the standard of review remains entire fairness. This demonstrates that even when disinterested and independent directors are negotiating the transaction, there is still a reasonably conceivable inference that they did not act independently. It is therefore consistent with that approach that they would not be entitled to the benefit of a pleading requirement that is only available when there is no inference or specter of disloyalty.

Practical Implications

The Cornerstone Therapeutics decision, particularly when read together with Swomley v. Schlecht, confirms that even if the corporation's charter contains a 102(b)(7) provision, disinterested and independent directors do not stand to benefit from it at the motion-to-dismiss stage when they negotiate a transaction with a controlling stockholder that does not meet the M & F Worldwide test for business judgment. Although this may have been understood or assumed following the Orchard Enterprises decision, Cornerstone Therapeutics indicates that Orchard was limited to motions for summary judgment.
The concerns raised in Cornerstone Therapeutics, however, remain valid. The law as it stands under Emerald Partners II would seem to provide a disincentive for disinterested and independent directors to join a special committee to negotiate with a controlling stockholder, because they put themselves in a position where plaintiffs will not have to allege that they breached a fiduciary duty. This may provide reason for the Delaware Supreme Court to revisit the issue, in addition to the need to resolve the discrepancy between Orchard and Southern Peru. Until then, the Cornerstone Therapeutics decision can also be taken as an added incentive for directors to encourage controlling stockholders to structure their transactions to satisfy M & F Worldwide, where possible.